NCT02783976View on ClinicalTrials.gov

Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice

CompletedOBSERVATIONAL

Enrollment

25

Participants

Timeline

Start Date

October 28, 2016

Primary Completion Date

June 20, 2018

Study Completion Date

June 20, 2018

Conditions

HCV Infection

Interventions

DRUG

Sovaldi

Sovaldi 400 mg tablets administered orally once daily

Trial Locations (6)

44680

Guadalajara

64460

Monterrey

Unknown

Cuernavaca

Durango

Guadalajara

Mexico City

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY